Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Amortization of Deferred Charges: 2019-2022

Historic Amortization of Deferred Charges for Viking Therapeutics (VKTX) over the last 3 years, with Mar 2022 value amounting to $77,000.

  • Viking Therapeutics' Amortization of Deferred Charges rose 6.94% to $77,000 in Q1 2022 from the same period last year, while for Mar 2022 it was $301,000, marking a year-over-year increase of 7.12%. This contributed to the annual value of $296,000 for FY2021, which is 6.86% up from last year.
  • According to the latest figures from Q1 2022, Viking Therapeutics' Amortization of Deferred Charges is $77,000, which was up 1.32% from $76,000 recorded in Q4 2021.
  • In the past 5 years, Viking Therapeutics' Amortization of Deferred Charges ranged from a high of $77,000 in Q1 2022 and a low of $64,000 during Q1 2019.
  • In the last 3 years, Viking Therapeutics' Amortization of Deferred Charges had a median value of $72,000 in 2021 and averaged $72,222.
  • Data for Viking Therapeutics' Amortization of Deferred Charges shows a peak YoY increased of 7.58% (in 2020) over the last 5 years.
  • Over the past 4 years, Viking Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $66,000 in 2019, then grew by 7.58% to $71,000 in 2020, then rose by 7.04% to $76,000 in 2021, then increased by 6.94% to $77,000 in 2022.
  • Its last three reported values are $77,000 in Q1 2022, $76,000 for Q4 2021, and $75,000 during Q3 2021.